Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,844.19
-0.17%
DAX
26,391.42
+0.26%
CAC 40
8,714.94
-0.13%
STOXX 50
6,551.22
+0.24%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Monday 17 November 2014 12:15 am  |  Updated:  Friday 07 June 2019 5:00 pm

Botox maker Allergan in £40bn takeover agreement with rival Actavis

By: Michael Bow

Add as a preferred source on Google

Botox maker Allergan is set to fall into the hands of Dublin-based rival Actavis after the two firms last night neared a landmark $62.5bn (£40bn) takeover agreement.
 
The deal, which would be Actavis’ third big takeover in a year, is expected to be unveiled as soon as today after it offered up to $215 a share for New York-listed Allergan, valuing it at between $62.5bn and $64bn.
 
Actavis, which has a substantial UK workforce in Devon and Liverpool, declined to comment last night. Allergan did not return calls seeking comment. 
 
A takeover would draw to a close Allergan’s hostile pursuit by pharma rival Valeant Pharmaceutical, which combined with hedge fund boss Bill Ackman earlier this year to chase the company. 
 
It had offered to pay $200 a share last month, an offer Allergan described as “grossly inadequate”. 
 
Allergan, which is led by London-born British chief executive David Pyott, also raised concerns about the group’s plans for investment into the company. 
 
The arrival of Actavis as a white knight marks the firm’s third mega takeover since last October, and underscores the M&A boom in the pharmaceuticals sector this year.  
 
The company swooped for Warner Chilcot in October 2013 in a deal valued at $8.5bn and made another giant leap by buying Forest Lab­or­atories in a stock and cash deal worth $25bn in July. 
 
The pharmaceutical sector has seen a bevy of multi-billion pound deals this year, including the $16bn sale by GlaxoSmithKline of a division to Novartis. However, many have been scuppered, including the mooted takeover of AstraZeneca by Pfizer and the $54bn purchase of Shire by AbbVie, which was ended due to tax reasons.  
 
Pyott, who was given a CBE by the Queen in 2006 and studied at University College London, has been working with bankers from Goldman Sachs and Bank of America Merrill Lynch to fend off Valeant’s approach in recent months. 
 
Actavis has previously worked with bankers from Greenhill & Co on the Forest takeover during the summer. 
 

PHARMA DEAL BY NUMBERS

Actavis

Market cap: $64.6bn
 
2013 Revenues: $8.7bn 
 
Staff: 25,000
 
HQ: Dublin, Ireland
 
UK Locations: Barnstaple, Devon and Speke, Liverpool 
 
Last share price: $243.77
 

Allergan

Market cap: $59.2bn
 
2013 Revenues: $6.3bn 
 
Staff: 11,500
 
HQ: California, USA 
 
UK Locations: Marlow, Buckinghamshire 
 
Last share price: $198.65
 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Mergers and acquisitions

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Easyjet extends window for another Castlelake bid

    Aviation
    EasyJet aircraft parked at the airport terminal ready for boarding, featuring distinctive orange branding and clear blue sky.
  • ‘We are going to run out’: Mitie marks eleventh mega takeover of 2026

    Markets
    The FTSE 100 enjoyed a 3-year record rally in the third quarter.
  • Easyjet board reaches agreement over £5.2bn Castlelake takeover

    Markets
    EasyJet airplane at airport terminal with passengers boarding, representing airline industry and travel news updates
  • FTSE 100 firm agrees £5.7bn takeover in latest private equity swoop

    Markets
    GettyImages 2211256637 showing a significant event or figure relevant to recent news updates in the business sector
  • Shareholder backlash pushes up low-ball London takeover bids

    Markets
    Over 100 major London-listed companies, including Fevertree Drinks and YouGov, have written to the Chancellor warning that the uncertainty surrounding the future of a key tax relief tied to London’s junior stock market is battering investor confidence. 
  • Prologis ramps up pressure on FTSE 100 property giant Segro

    Property
    David Sleath, Chief Executive Officer, delivering a speech at a business conference with a focused expression.
  • Mike Ashley’s Frasers feels lift from takeover spree

    Retail
    Mike Ashley, founder of Frasers Group Plc. Photographer: Chris J. Ratcliffe/Bloomberg via Getty Images
  • FTSE 100 property firm slams ‘opportunistic, one-sided, inadequate’ takeover offer

    Property
    David Sleath, Chief Executive Officer, delivering a speech at a business conference with a focused expression.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook